GLP-1 / GIP agonist

Tirzepatide

Also known as Mounjaro, Zepbound

Dual-hormone agonist with even stronger weight loss than semaglutide.

Clinical evidence

Overview

Tirzepatide is a dual-hormone agonist that activates both GLP-1 and GIP receptors simultaneously, producing greater appetite control and metabolic effect than GLP-1 alone. It is sold under the brand names Mounjaro and Zepbound and is FDA-approved. Clinical trials have shown tirzepatide achieving larger average weight loss than semaglutide, making it one of the most effective pharmaceutical options for fat loss currently available. Activating both GLP-1 and GIP receptors together appears to create a more powerful signal to the brain and gut than either receptor alone. The result is stronger appetite suppression and better blood sugar regulation. Timezpatide is primarily indicated for people whose main goal is significant fat loss. It also has some supporting evidence for long-term metabolic health and longevity. The medication is taken as a once-weekly subcutaneous injection on the same day each week. Doses range from 2.5 mg up to 15 mg and are titrated gradually based on response and tolerability. The slow titration schedule is intended to minimize gastrointestinal side effects. GI side effects - particularly nausea - are the most commonly reported. The same thyroid cancer caution that applies to semaglutide applies here: tirzepatide is not appropriate for those with a personal or family history of medullary thyroid cancer. It should not be used during pregnancy. Tirzepatide cannot be combined with other GLP-1 agonists including semaglutide, retatrutide, or liraglutide. Cagrilintide (an amylin analog) is considered a compatible stack, and clinicians sometimes combine the two for additional satiety. Your exact dose, titration plan, and any stacking decisions are set with a licensed provider in the PepDepo network at consult.

At a glance

Route

SC injection

Dose

2.5-15 mg

Frequency

Once weekly

Timing

Same day each week

Cycle

Ongoing under supervision

Combining

Stacks well with: Cagrilintide

Avoid combining with: Semaglutide, Retatrutide

Safety

GI side effects; same thyroid cancer caution as other GLP-1s.

Regulatory: FDA-approved (Mounjaro/Zepbound).

Not appropriate if: pregnant.

Questions

What makes tirzepatide different from semaglutide?⌄

Tirzepatide activates two receptors - GLP-1 and GIP - while semaglutide only targets GLP-1. Hitting both receptors together produces greater appetite suppression and metabolic effect, which is reflected in larger average weight loss numbers in clinical trials.

How is tirzepatide taken?⌄

Once-weekly subcutaneous injection, always on the same day of the week. Doses start at 2.5 mg and are stepped up gradually to a maximum of 15 mg based on your response.

Who is this typically used for?⌄

Primarily people looking for significant fat loss. It is particularly relevant when semaglutide has not produced adequate results or when a stronger metabolic response is the clinical goal.

What side effects are most common?⌄

GI side effects, especially nausea, are the most frequently reported. These are managed through the slow titration protocol. Most people find them most pronounced in the first weeks at each new dose level.

Are there safety contraindications I should know about?⌄

Tirzepatide carries the same thyroid cancer caution as other GLP-1 agonists - it is not appropriate if you or a close family member has a history of medullary thyroid cancer. It is also not appropriate during pregnancy.

Can I take it with other weight-loss peptides?⌄

It cannot be combined with semaglutide, retatrutide, or liraglutide. Cagrilintide is listed as a compatible companion that some clinicians stack with it for added satiety.

Want a personalized protocol?

Exact dosing is set with a licensed provider in the PepDepo network. This page is education, not a prescription.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.